These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1762838)

  • 21. Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy.
    Fenstermacher J; Gazendam J
    Cancer Treat Rep; 1981; 65 Suppl 2():27-37. PubMed ID: 7346144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
    Miyagami M; Kagawa Y; Tsubokawa T
    No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy of brain tumor (author's transl)].
    Hoshino T
    No To Shinkei; 1976 Aug; 28(8):739-50. PubMed ID: 799933
    [No Abstract]   [Full Text] [Related]  

  • 24. Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.
    Chamberlain MC
    Expert Rev Neurother; 2010 Apr; 10(4):547-61. PubMed ID: 20367207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
    Kemper EM; Boogerd W; Thuis I; Beijnen JH; van Tellingen O
    Cancer Treat Rev; 2004 Aug; 30(5):415-23. PubMed ID: 15245774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
    Deeken JF; Löscher W
    Clin Cancer Res; 2007 Mar; 13(6):1663-74. PubMed ID: 17363519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).
    van Vulpen M; Kal HB; Taphoorn MJ; El-Sharouni SY
    Oncol Rep; 2002; 9(4):683-8. PubMed ID: 12066192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system.
    Mellett LB
    Cancer Treat Rep; 1977 Jul; 61(4):527-31. PubMed ID: 884690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemotherapy of malignant brain tumours: principles, difficulties, results and strategies (author's transl)].
    Mennel HD; Heiss WD
    Wien Klin Wochenschr; 1980 Sep; 92(17):591-602. PubMed ID: 6256978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amphotericin B and the blood-brain barrier to methotrexate.
    Barry DI; Paulson OB
    Neurosurgery; 1982 Feb; 10(2):224-6. PubMed ID: 7070618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemotherapy of brain tumors: biological basis of its limited efficacy].
    Mousseau M
    Bull Cancer; 1994 May; 81(5):414-24. PubMed ID: 7749219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
    Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA
    Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular complication of combined intracarotid chemotherapy and osmotic blood-brain barrier disruption.
    Suda K; Nakasu S; Saito A
    Nihon Geka Hokan; 1985 Sep; 54(5):359-63. PubMed ID: 3938210
    [No Abstract]   [Full Text] [Related]  

  • 34. Chemotherapy for primary brain tumors.
    Allen JC
    Pediatr Ann; 1978 Dec; 7(12):81-5. PubMed ID: 740428
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacodynamics and the blood-brain barrier.
    Blasberg RG
    Natl Cancer Inst Monogr; 1977 Dec; 46():19-27. PubMed ID: 349396
    [No Abstract]   [Full Text] [Related]  

  • 36. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors.
    Haluska M; Anthony ML
    Clin J Oncol Nurs; 2004 Jun; 8(3):263-7. PubMed ID: 15208820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.
    Parrish KE; Sarkaria JN; Elmquist WF
    Clin Pharmacol Ther; 2015 Apr; 97(4):336-46. PubMed ID: 25669487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
    Fety R; Lucas C; Solere P; Cour V; Vignoud J
    Cancer Chemother Pharmacol; 1992; 31(2):118-22. PubMed ID: 1451232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.
    Addeo R; Zappavigna S; Luce A; Facchini S; Caraglia M
    Expert Opin Drug Saf; 2013 Sep; 12(5):729-40. PubMed ID: 23560594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New methods of drug delivery through the blood brain barrier].
    Bruhn C
    Dtsch Med Wochenschr; 2012 May; 137(21):p18. PubMed ID: 22622506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.